Deucravacitinib in Plaque Psoriasis: 3-Year Safety and Efficacy Results From the Phase 3 POETYK PSO-1 and PSO-2 Trials. J of Skin 2023, 7 (6), s240. https://doi.org/10.25251/skin.7.supp.240.